[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] [$rhhbys](/topic/$rhhbys) ### Top Social Posts *Showing only X posts for non-authenticated requests. Use your API key in requests for full results.* "It looks like AAV gene therapy is finding its niche: local delivery of relatively low doses (E10-E12 total vg) in tissues as contained as possible. Recent clinical wins by $QURE's AMT-130 (intra-parenchymal Huntington's) and $REGN's DB-OTO (intracochlear inherited deafness) support this trend. These follow prior approved drugs like $RHHBY's Luxturna (subretinal LCA2) and $PTCT's Upstaza (intra-parenchymal AADC deficiency) also delivered locally. $NVS' Zolgensma is a special case -- although delivered systemically at relatively high doses the infant BBB remains permissive allowing efficient" [X Link](https://x.com/GerardCaelles/status/1977771288660791721) [@GerardCaelles](/creator/x/GerardCaelles) 2025-10-13T16:19Z 1099 followers, 13.8K engagements "Interesting take on the FcRH5 landscape which seems to be one of $RHHBY's main oncology R&D areas of interest. $MRNA & $LEGN active here" [X Link](https://x.com/JacobPlieth/status/1970769553572454869) [@JacobPlieth](/creator/x/JacobPlieth) 2025-09-24T08:37Z 30.9K followers, 4482 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"It looks like AAV gene therapy is finding its niche: local delivery of relatively low doses (E10-E12 total vg) in tissues as contained as possible. Recent clinical wins by $QURE's AMT-130 (intra-parenchymal Huntington's) and $REGN's DB-OTO (intracochlear inherited deafness) support this trend. These follow prior approved drugs like $RHHBY's Luxturna (subretinal LCA2) and $PTCT's Upstaza (intra-parenchymal AADC deficiency) also delivered locally. $NVS' Zolgensma is a special case -- although delivered systemically at relatively high doses the infant BBB remains permissive allowing efficient"
X Link @GerardCaelles 2025-10-13T16:19Z 1099 followers, 13.8K engagements
"Interesting take on the FcRH5 landscape which seems to be one of $RHHBY's main oncology R&D areas of interest. $MRNA & $LEGN active here"
X Link @JacobPlieth 2025-09-24T08:37Z 30.9K followers, 4482 engagements
/topic/$rhhbys/posts